Tissue Repair Ltd AI Stock Analysis
Want to see AU:TRP full AI Analyst Report?
Tissue Repair Ltd (TRP) AI Stock Analysis
Tissue Repair Ltd
(ASX:TRP)
The score is held down primarily by weak financial performance (persistent losses, sharp 2026 revenue decline, and ongoing/increasing cash burn despite a debt-free balance sheet). Technicals provide partial offset due to a strong trend and positive MACD, but the very high RSI suggests an overbought setup. Valuation is constrained by negative earnings (negative P/E) and no stated dividend yield.
Tissue Repair Ltd (TRP) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 5.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 96.69K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 1.28
- Revenue Growth
- 32.22%
- EPS Growth
- -26.53%
- Country
- Australia
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Tissue Repair Ltd Business Overview & Revenue Model
Company Description
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recover...
Tissue Repair Ltd Financial Statement Overview
Summary
Overall fundamentals are weak: the income statement shows persistent losses and a sharp revenue drop in 2026 (~-75.5% vs. 2025) with profitability deteriorating to negative gross profit. Cash flow remains consistently negative with increased cash burn in 2026, indicating ongoing funding dependence. The balance sheet is a relative strength due to zero debt, but equity has fallen materially (2022–2026) and ROE is deeply negative, reflecting capital base erosion.
Income Statement
18Very NegativeBalance Sheet
66PositiveCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.28M | 559.70K | 2.63M | 152.24K | 3,076 | 171.92K |
| Gross Profit | 1.98M | -1.80M | 2.63M | 150.51K | 428 | 170.21K |
| EBITDA | -4.81M | -7.75M | -4.72M | -6.51M | -5.14M | -7.01M |
| Net Income | -3.85M | -5.36M | -4.24M | -4.14M | -4.17M | -6.84M |
Balance Sheet | ||||||
| Total Assets | 12.44M | 10.34M | 14.57M | 19.39M | 22.38M | 25.90M |
| Cash, Cash Equivalents and Short-Term Investments | 8.29M | 4.77M | 12.32M | 16.44M | 21.40M | 25.46M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 607.50K | 1.57M | 662.53K | 1.35M | 497.35K | 559.64K |
| Stockholders Equity | 11.83M | 8.77M | 13.91M | 18.04M | 21.88M | 25.34M |
Cash Flow | ||||||
| Free Cash Flow | -5.70M | -7.55M | -4.12M | -4.95M | -4.26M | -3.97M |
| Operating Cash Flow | -5.27M | -7.50M | -3.70M | -4.95M | -4.26M | -3.97M |
| Investing Cash Flow | -432.20K | -43.65K | -421.67K | -3,355 | -2,244 | -3,924 |
| Financing Cash Flow | 0 | 0 | 0 | 0 | 0 | 21.36M |
Tissue Repair Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.09, and above the 200-day MA of 0.12, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 75.88 is Negative, neither overbought nor oversold. The STOCH value of 47.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:TRP.
Tissue Repair Ltd Peers Comparison
Overall Rating
AU:MSB70Outperform- AU:TRP50Neutral
AU:OCC44Neutral
AU:ACR43Neutral
AU:CMB39Underperform
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:MSB | 70Outperform | AUD 2.71B | -30.92 | -10.06% | ― | 555.67% | 49.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:TRP | 50Neutral | AUD 6.92M | -1.24 | -52.04% | ― | 32.22% | -26.53% |
| AU:OCC | 44Neutral | AUD 162.07M | -10.94 | -36.83% | ― | 51.07% | -47.63% |
| AU:ACR | 43Neutral | AUD 5.51M | -6.43 | -45.29% | ― | 290.25% | 92.05% |
| AU:CMB | 39Underperform | AUD 10.60M | -1.43 | -247.44% | ― | -4.24% | 33.39% |
| AU:BOT | 38Underperform | AUD 24.86M | -0.28 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:TRP | Tissue Repair Ltd | 0.13 | -0.17 | -56.67% | |
| AU:ACR | Acrux Limited | 0.01 | -0.00 | -33.33% | |
| AU:MSB | Mesoblast Limited | 2.03 | -0.28 | -12.12% | |
| AU:OCC | Orthocell Ltd | 0.58 | -0.52 | -47.27% | |
| AU:CMB | Regeneus Ltd. | 0.36 | -0.14 | -28.00% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.00% |
Tissue Repair Ltd Corporate Events
Tissue Repair cancels shares in equal access buy-back
Tissue Repair Ltd has cancelled 7,198,783 ordinary fully paid shares under an equal access buy-back scheme, as notified in an Appendix 3H filing to the ASX dated October 30, 2026. The reduction in issued capital may improve capital management efficie...
Tissue Repair completes $935,000 off-market share buy-back
Tissue Repair Limited has completed its off-market equal access share buy-back, receiving valid applications from 172 eligible shareholders for 7,198,783 shares, below the buy-back limit of 7,692,307 shares. As a result, no scale-back will apply and...
Tissue Repair Completes Equal Access Share Buy-Back
Tissue Repair Ltd has completed an equal access share buy-back of its ordinary fully paid shares, repurchasing a total of 7,198,783 securities. The company paid aggregate consideration of approximately AUD 935,842 for the buy-back, marking the final...
Tissue Repair Sets November AGM as Chair Signals Support for Resolutions
Tissue Repair Limited has called its Annual General Meeting for 24 November 2026 in Sydney, giving shareholders the opportunity to vote on key matters affecting the company. The notice of meeting will be distributed mainly via electronic channels, wi...
Tissue Repair Outlines Equal Access Share Buy-Back Structure
Tissue Repair Ltd has released a buy-back offer booklet outlining an equal access off-market share buy-back open to eligible shareholders during a defined offer period. The company sets out how issuer-sponsored and CHESS holders, including trustees,...
Tissue Repair Sets 2026 AGM as Late-Stage Wound-Healing Pipeline Advances
Biotechnology developer Tissue Repair Limited, which specialises in second-generation wound healing therapies and is advancing its TR987 candidate into Phase 3 trials for chronic wounds, has outlined a broader pipeline including the TR Pro+ post-proc...
Tissue Repair Launches Equal Access Share Buy-Back on ASX
Tissue Repair Ltd has announced an equal access share buy-back of its ordinary fully paid shares listed on the ASX under code TRP. The move signals a capital management initiative that could enhance earnings per share and adjust the company’s capital...
Tissue Repair Shareholders Approve Delisting and Equal Access Buyback
Tissue Repair Limited, a Phase 3-stage biotechnology company, is developing second-generation wound healing therapies for chronic and acute wounds, alongside a post-procedure topical gel aimed at enhancing recovery and skin quality after cosmetic and...
Tissue Repair taps veteran medtech financier as new CFO
Tissue Repair Ltd has appointed experienced medtech and life sciences finance executive Mark Bouw as its new fractional Chief Financial Officer, effective 10 September 2026. Bouw, founder and CEO of specialist advisory firm Straterra Australia, bring...
Tissue Repair Brings TR Pro+ Distribution Back In-House in Australasia
Tissue Repair Limited has resumed direct distribution and management of its TR Pro+® hydrogel in the aesthetic market across Australia and New Zealand, bringing these activities back in-house to sit alongside its existing direct distribution in the m...
Tissue Repair Limited Confirms ASX-Aligned Governance for 2026
Tissue Repair Limited, an ASX-listed healthcare company focused on tissue repair solutions, operates under Australia’s corporate governance regime and provides investors with structured oversight of its board and management. The business maintains de...
Tissue Repair Widens Annual Loss as Net Tangible Assets Decline
Tissue Repair Ltd reported a marginal 0.4% decline in revenue to $3.21 million for the year ended 30 June 2026, while its net loss widened by 26.5% to $5.36 million, underscoring ongoing profitability challenges despite relatively stable top-line per...
Tissue Repair Plans ASX Delisting and $1m Share Buy-Back
Biotechnology developer Tissue Repair Ltd, which specialises in second-generation wound healing therapies, is progressing a pipeline led by its Phase 3 chronic wound candidate TR987 and supported by post-procedure gel TR Pro+ and other acute wound pr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026